mRNA expression of DOK1-6 in human breast cancer

Table 1 Clinical and pathological data

Parameter number	Category	n
Node status	Positive	54
	Negative	73
Tumour grade	1	24
	2	43
	3	58
Tumour type	Ductal	98
	Lobular	14
	Medullary	2
	Tubular	2
	Mucinous	4
	Other	7
TNM staging	1	70
	2	40
	3	7
	4	4
NPI	1	68
	2	38
	3	16
Clinical outcome	Disease-free	90
	With local recurrence	5
	Alive with metastasis	7
	Died of breast cancer	16

Missing values reflect discarded/un-interpretable values. NPI: Nottingham Prognostic Index.

Table 2 DOKs and CK19 primers

Gene	Forward	Reverse
DOK-1	TGGCCCTACACTCTGTTG	ACTGAACCTGACCGTACAGGAAGGTGAAGGTTCCAG
DOK-2	ACTGGCCCTACAGGTTTC	ACTGAACCTGACCGTACACTCAAAGTTGCCCTCTCC
DOK-3	AGAAGGGGAAGTGTGAGG	ACTGAACCTGACCGTACATCCTTGATAGGGGTCTCC
DOK-4	GCCTCAACGACATCAGTC	ACTGAACCTGACCGTACACCATACACGTCCAGGTTG
DOK-5	CGTGGTTCACTTTTGAGG	ACTGAACCTGACCGTACAGCAGCAGAGTGGACTTTC
DOK-6	AGAACAGCGTTGGTGAAA	ACTGAACCTGACCGTACAAGCTGGGAAATGTCTGTG
CK19	CAGGTCCGAGGTTACTGAC	ACTGAACCTGACCGTACACACTTTCTGCCAGTGTGTCTTC

DOK: Downstream of tyrosine kinase; CK19: Cytokeratin 19.

Table 3 Downstream of tyrosine kinases (1-3) mRNA expression levels (mean ± SD)

Patient and tumour characteristics	DOK-1	P	DOK-2	P	DOK-3	P
NPI
1 vs 2	2250 ± 4652 vs 3988 ± 7824	0.48	4.37 ± 10.32 vs 4.14 ± 12.26	0.950	6802 ± 18036 vs 37024 ± 127523	0.150
1 vs 3	2250 ± 4652 vs 942 ± 1395	0.19	4.37 ± 10.32 vs 1.57 ± 4.55	0.270	6802 ± 18036 vs 9808 ± 19782	0.600
2 vs 3	3988 ± 7824 vs 942 ± 1395	0.21	4.14 ± 12.26 vs 1.57 ± 4.55	0.420	37024 ± 127523 vs 9808 ± 19782	0.210
Tumour grade
1 vs 2	1346 ± 2587 vs 3886 ± 6155	0.18	0.651 ± 1.837 vs 4.63 ± 12.49	0.190	1259 ± 2797 vs 37803 ± 126737	0.084
1 vs 3	1346 ± 2587 vs 2100 ± 5520	0.58	0.651 ± 1.837 vs 4.23 ± 10.15	0.092	1259 ± 2797 vs 8954 ± 23276	0.022
2 vs 3	3886 ± 6155 vs 2100 ± 5520	0.37	4.63 ± 12.49 vs 4.23 ± 10.15	0.910	37803 ± 126737 vs 8954 ± 23276	0.170
TNM
1 vs 2	2507 ± 4800 vs 3553 ± 7084	0.62	6.62 ± 13.46 vs 1.195 ± 3.782	0.052	26175 ± 101693 vs 4508 ± 9938	0.100
1 vs 3	2507 ± 4800 vs 0.782 ± 1.38	0.01	6.62 ± 13.46 vs 0.00562 ± 0.00942	0.015	26175 ± 101693 vs 16879 ± 39061	0.640
1 vs 4	2507 ± 4800 vs 626 ± 1252	0.11	6.62 ± 13.46 vs 0.00001 ± 0.00001	0.015	26175 ± 101693 vs 83.2 ± 80.9	0.050
2 vs 3	3553 ± 7084 vs 0.782 ± 1.38	0.07	1.195 ± 3.782 vs 0.00562 ± 0.00942	0.190	4508 ± 9938 vs 16879 ± 39061	0.440
2 vs 4	3553 ± 7084 vs 626 ± 1252	0.15	1.195 ± 3.782 vs 0.00001 ± 0.00001	0.190	4508 ± 9938 vs 83.2 ± 80.9	0.014
3 vs 4	0.782 ± 1.38 vs 626 ± 1252	0.39	0.00562 ± 0.00942 vs 0.00001 ± 0.00001	0.320	16879 ± 39061 vs 83.2 ± 80.9	0.300
Survival
DF vs LR	1839 ± 4089 vs 1957 ± 2149	0.95	3.94 ± 8.96 vs 0.00001 ± 0.00001	0.009	18203 ± 86910 vs 16027 ± 40813	0.910
DF vs DR	1839 ± 4089 vs 12051 ± 17043	0.55	3.94 ± 8.96 vs 0.00246 ± 0.00349	0.009	18203 ± 86910 vs 11083 ± 22940	0.620
DF vs DR	1839 ± 4089 vs 3023 ± 6758	0.72	3.94 ± 8.96 vs 5.93 ± 17.43	0.750	18203 ± 86910 vs 21264 ± 60618	0.880

DOK: Downstream of tyrosine kinase; NPI: Nottingham Prognostic Index; DF: Disease Free; LR: Local Recurrence; DR: Distant Recurrence.

Table 4 Downstream of tyrosine kinases (4-6) mRNA expression levels (mean ± SD)

Patient and tumour characteristics	DOK-4	P	DOK-5	P	DOK-6	P
NPI
1 vs 2	415 ± 1444 vs 94.7 ± 275	0.170	31504 ± 163256 vs 2466 ± 7194	0.23	15.4 ± 39.98 vs 7.55 ± 18.37	0.270
1 vs 3	415 ± 1444 vs 103.4 ± 182.6	0.180	31504 ± 163256 vs 88648 ± 287508	0.52	15.4 ± 39.98 vs 0.218 ± 0.468	0.018
2 vs 3	94.7 ± 275 vs 103.4 ± 182.6	0.910	2466 ± 7194 vs 88648 ± 287508	0.32	7.55 ± 18.37 vs 0.218 ± 0.468	0.048
Tumour grade
1 vs 2	589 ± 1860 vs 188 ± 819	0.410	68655 ± 261421 vs 5756 ± 14725	0.32	12.96 ± 28.62 vs 12.41 ± 39.55	0.960
1 vs 3	589 ± 1860 vs 147.5 ± 623.8	0.350	68655 ± 261421 vs 28639 ± 155311	0.55	12.96 ± 28.62 vs 6.22 ± 21.56	0.430
2 vs 3	188 ± 819 vs 147.5 ± 623.8	0.830	5756 ± 14725 vs 28639 ± 155311	0.35	12.41 ± 39.55 vs 6.22 ± 21.56	0.440
TNM
1 vs 2	229 ± 829 vs 403 ± 1568	0.610	27103 ± 152075 vs 5096 ± 19916	0.30	10.26 ± 33.54 vs 13.68 ± 32.53	0.680
1 vs 3	229 ± 829 vs 83.9 ± 222	0.330	27103 ± 152075 vs 200882 ± 446722	0.44	10.26 ± 33.54 vs 2.07 ± 4.62	0.130
1 vs 4	229 ± 829 vs 49.4 ± 62.1	0.160	27103 ± 152075 vs 0.198 ± 0.184	0.20	10.26 ± 33.54 vs 0.0734 ± 0.1464	0.048
2 vs 3	403 ± 1568 vs 83.9 ± 222	0.340	5096 ± 19916 vs 200882 ± 446722	0.38	13.68 ± 32.53 vs 2.07 ± 4.62	0.098
2 vs 4	403 ± 1568 vs 49.4 ± 62.1	0.280	5096 ± 19916 vs 0.198 ± 0.184	0.11	13.68 ± 32.53 vs 0.0734 ± 0.1464	0.047
3 vs 4	83.9 ± 222 vs 49.4 ± 62.1	0.720	200882 ± 446722 vs 0.198 ± 0.184	0.37	2.07 ± 4.62 vs 0.0734 ± 0.1464	0.340
Survival
DF vs LR	328 ± 1205 vs 2.22 ± 2.5	0.038	23013 ± 139049 vs 10477 ± 22630	0.53	11.38 ± 33.96 vs 9.24 ± 18.47	0.840
DF vs DR	328 ± 1205 vs 40.5 ± 77.9	0.074	23013 ± 139049 vs 1022 ± 2240	0.21	11.38 ± 33.96 vs 20.7 ± 35.8	0.700
DF vs DR	328 ± 1205 vs 84.1 ± 185	0.140	23013 ± 139049 vs 81855 ± 276356	0.47	11.38 ± 33.96 vs 0.209 ± 0.45	0.013

DOK: Downstream of tyrosine kinase; NPI: Nottingham Prognostic Index; DF: Disease Free; LR: Local Recurrence; DR: Distant Recurrence.